PET and SPECT for radiation treatment planning

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 2, 2012, Pages 163-172

  Gotz I ^a   Spehl, T S ^a   Weber, W A ^a   Grosu, A L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Magnetic resonance imaginmg; Positron emission tomography; Radiotherapy

Indexed keywords

AMINO ACID; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTYROSINE F 18; GADOLINIUM; GALLIUM 68; IODINE 123; METHIONINE C 11; METIROSINE; TETRAXETAN; TRACER; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; BLOOD BRAIN BARRIER; BRAIN LYMPHOMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL (TOPIC); COLLIMATOR; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG HALF LIFE; DRUG UPTAKE; GLIOBLASTOMA; GLIOMA; GLOMUS TUMOR; HISTOPATHOLOGY; HUMAN; IMAGE GUIDED RADIOTHERAPY; IMAGING SYSTEM; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MENINGIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROGNOSIS; RADIATION DOSE; RADIATION NECROSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTIC BIOPSY; TREATMENT PLANNING; TUMOR RECURRENCE; TUMOR VOLUME;

BRAIN NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84864381206     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009;22:633-8.
2. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405-10.
3. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 2003;9:180-8. (Pubitemid 36944725)
4. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep 2009;9:241-6.
5. Watling CJ, Lee DH, Macdonald DR, Cairncross JG. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994;12:1886-9. (Pubitemid 24349391)
6. Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F et al. [11C]L-methionine uptake in gliomas. Neurosurgery 1989;25:720-8.
7. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993;186:45-53. (Pubitemid 23005465)
8. Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999;40:1367-73. (Pubitemid 29385647)
9. Langen KJ, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH. Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionine. Journal of nuclear medicine: official publication. Society of Nuclear Medicine 2000;41:1250-5.
10. Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998;18:500-9. (Pubitemid 28213534)
11. Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergstrom M et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 1989;30:225-32. (Pubitemid 19152548)
12. Kracht LW, Miletic H, Busch S.Jacobs AH, Voges J, Hoevels M et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-70. (Pubitemid 39487701)
13. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F et al. An Interindividual Comparison of O-(2-[(18)F] Fluoroethyl)-L-Tyrosine (FET)- and L-[Methyl-(11)C]Methionine (MET)-PET in Patients With Brain Gliomas and Metastases. Int J Radiat Oncol Biol Phys 2011;81:1049-58.
14. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;80:176-84.
15. Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K et al. Usefulness of L-[methyl-11C]methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005;103:498-507. (Pubitemid 43186642)
16. Rachinger W, Goetz C, Ppperl G, Gildehaus FJ, Kreth FW, Holtmannsptter M et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005;57:505-11. (Pubitemid 41254459)
17. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med Mol Imaging 2000;27:542-9. (Pubitemid 30262620)
18. Grosu AL, Astner ST, Riedel E, Nieder C, Lumenta CB, Schwaiger M et al. O-(2-(18F)Fluorethyl)-L-tyrosine and L-(Methyl-11C)-Methionine PET for Determination of Tumor Extension in Gliomas and Brain Metastases. Int J Radiat Oncol Biol Phys 2011 Nov 15;81(4):1049-58.
19. Astner ST, Grosu AL, Weber WA, Wester HJ, Schwaiger M, Molls M. O-(2-(18F)Fluorethyl)-L-Tyrosine Compared to L-(Methyl-11)Methionine in Positron Emission Tomography for Tumor Volume Delineation of Gliomas and Metastases. ASTRO; October 16-20, 2005; Denver. Int J Radiat Oncol Biol Phys 2005:S65.
20. Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-oncology 2011;13:307-16.
21. Weckesser M, Langen KJ, Ricken CH, Kloska S, Straeter R, Harnacher K et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32:422-9. (Pubitemid 40591174)
22. Thiele F, Ehmer J, Piroth MD, Eble MJ, Coenen HH, Kaiser HJ et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol 2009;54:5525-39.
23. Moulin-Romsee G, D'Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging 2007;34:2082-7. (Pubitemid 350212139)
24. Borgwardt L, Hojgaard L, Carstensen H, Laursen H, Nowak M, Thomsen C et al. Increased fluorine-182-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 2005;23:3030-7. (Pubitemid 46224124)
25. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816-22. (Pubitemid 15009404)
26. Barker FG 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115-26. (Pubitemid 26425516)
27. Podoloff DA, Ball DW, Ben-Josef E, Benson AB 3rd, Cohen SJ, Coleman RE et al. NCCN task force: clinical utility of PET in a variety of tumor types. Journal of the National Comprehensive Cancer Network: JNCCN 2009;7(Suppl 2):S1-26.
28. Hoffman JM, Waskin HA, Schiffer T, Hanson MW, Gray L, Rosenfeld S et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567-75. (Pubitemid 23115656)
29. Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998;41:989-95. (Pubitemid 28377478)
30. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 2008;14:2049-55. (Pubitemid 351551115)
31. Jacobs AH, Kracht LW, Gossmann A, Ruger MA, Thomas AV, Thiel A et al. Imaging in neurooncology. NeuroRx 2005;2:333-47. (Pubitemid 40471440)
32. Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. Journal of nuclear medicine: official publication. Society of Nuclear Medicine 2006;47:410-8.
33. Biersack HJ, Grunwald F, Kropp J. Single photon emission computed tomography imaging of brain tumors. Semin Nucl Med 1991;21:2-10.
34. Langen KJ, Ziemons K, Kiwit JC, Herzog H, Kuweit T, Bock WJ et al. 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. Journal of nuclear medicine: official publication. Society of Nuclear Medicine 1997;38:517-22.
35. Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B et al. Influence of size of regions of interest on the measurement of uptake of 123I-alpha-methyl tyrosine by brain tumours. Nucl Med Commun 1996;17:609-15. (Pubitemid 26295396)
36. Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust P et al. Value of 123I-1MT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology 2005;47:18-26. (Pubitemid 40260309)
37. Grosu AL, Weber W, Feldmann HJ, Wuttke B, Bartenstein P, Gross MW et al. First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys 2000;47:517-26. (Pubitemid 30236396)
38. Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BF et al. Clinical value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 2002;20:396-404. (Pubitemid 34072521)
39. Guth-Tougelidis B, Muller S, Mehdorn MM, Knust EJ, Dutschka K, Reiners C. [Uptake of DL-3-123I-iodo-alpha-methyltyrosine in recurrent brain tumors]. Nuklearmedizin Nuclear Medicine 1995;34:71-5.
40. Henze M, Mohammed A, Schlemmer H, Herfarth KK, Mier W, Eisenhut M et al. Detection of tumour progression in the follow-up of irradiated low-grade astrocytomas: comparison of 3-[123I] iodo-alpha-methyl-L-tyrosine and 99mTc-MIBI SPET. Eur J Nucl Med Mol Imaging 2002;29:1455-61.
41. Langen KJ, Tatsch K, Grosu AL, Jacobs AH, Weckesser M, Sabri O. Diagnostics of cerebral gliomas with radiolabeled amino acids. Deutsches Amebian international 2008;105:55-61.
42. IAEA 2008. The role of PET CT in radiation treatment planning for cancer patient treatment [Internet], [cited 2012 March 26]. Available at: http://www-pub.iaea.org/MTCD/publications/PDF/te-1603-web.pdf
43. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363-78. (Pubitemid 29467035)
44. Grosu AL, Feldmann HJ, Stark S, Pinsker M, Nieder C, Kneschaurek P et al. [Stereotactic radiation therapy with a modified linear accelerator in patients with brain metastases]. Der Nervenarzt 2001;72:770-81.
45. Coope DJ, Cizek J, Eggers C, Vollmar S, Heiss WD, Herholz K. Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map. J Nucl Med 2007;48:1971-80. (Pubitemid 350232305)
46. Langen KJ, Bartenstein P, Boecker H, Brust P, Coenen HH, Drzezga A et al. [German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids]. Nuklearmedizin Nuclear Medicine 2011;50:167-73.
47. Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 2006;33:1374-80. (Pubitemid 44630797)
48. Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:64-74. (Pubitemid 41583543)
49. Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 2004;75:1457-62. (Pubitemid 39279817)
50. Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J et al. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009;73:479-85.
51. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-87. (Pubitemid 40380202)
52. Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 2007;48:519-27. (Pubitemid 47571405)
53. Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M et al. [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 2008;3:44.
54. Serizawa T, Saeki N, Higuchi Y, Ono J, Matsuda S, Sato M et al. Diagnostic value of thallium-201 chloride single-photon emission computerized tomography in differentiating tumor recurrence from radiation injury after gamma knife surgery for metastatic brain tumors. J Neurosurg 2005;102(Suppl):266-71. (Pubitemid 44783967)
55. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22. (Pubitemid 28240345)
56. Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECD/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy, Int J Radiat Oncol Biol Phys 2005;63:511-9. (Pubitemid 41317169)
57. Weber WA, Dick S, Reidl G, Dzewas B, Busch R, Feldmann HJ et al. Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med 2001;42:1144-50. (Pubitemid 32717829)
58. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 2011;52:856-64.
59. Popped G, Gotz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC et al. Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006;33:792-800. (Pubitemid 43979687)
60. Wurker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996;23:583-6. (Pubitemid 26140591)
61. Wen PY, Black PM, Loeffler JS. Metastatic brain cancer. In: DeVita V, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001. p. 2655-70.
62. Rush S, Elliott RE, Morsi A, Mehta N, Spriet J, Narayana A et al. Incidence, timing, and treatment of new brain metastases after Gamma Knife surgery for limited brain disease: the case for reducing the use of whole-brain radiation therapy. J Neurosurg 2011;115:37-48.
63. Rodrigues G, Eppinga W, Lagerwaard F, de Haan P, Haasbeek C, Perera F et al. A pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain metastases. Radiother Oncol 2011;2:2.
64. Maranzano E, Trippa F, Casale M, Costantini S, Anselmo P, Carletti S et al. Reirradiation of brain metastases with radiosurgery. Radiother Oncol 2011 [Epub ahead of print].
65. Bergstrom M, Collins VP, Ehrin E, Ericson K, Eriksson L, Greitz T et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983;7:1062-6. (Pubitemid 14246648)
66. Matsuo M, Miwa K, Shinoda J, Kako N, Nishibori H, Sakurai K et al. Target definition by C11-methionine-PET for the radiotherapy of brain metastases. Int J Radiat Oncol Biol Phys 2009;74:714-22.
67. Rottenburger C, Hentschel M, Kelly T, Trippel M, Brink I, Reithmeier T et al. Comparison of C-11 methionine and C-11 choline for PET imaging of brain metastases: a prospective pilot study. Clinical Nuclear Medicine 2011;36:639-42.
68. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005;23:1507-13.
69. Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007;69:1178-82. (Pubitemid 47517564)
70. Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006;33:164-8. (Pubitemid 43152883)
71. Kawase Y, Yamamoto Y, Kameyama R, Kawai N, Kudomi N, Nishiyama Y. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma. Mol Imaging Biol 2011;13:1284-9.
72. Ogawa T, Kanno I, Hatazawa J, Inugami A, Fujita H, Shimosegawa E et al. Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. Radiographics: a review publication of the Radiological Society of North America, Inc 1994;14:101-10.
73. Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M et al. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:339-44. (Pubitemid 44332720)
74. Grosu AL, Lachner R, Wiedenmann N, Stark S, Thamm R, Kneschaurek P et al. Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. Int J Radiat Oncol Biol Phys 2003;56:1450-63. (Pubitemid 36842898)
75. Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOCPET. Int J Radiat Oncol Biol Phys 2006;65:222-7.
76. Astner ST, Bundschuh RA, Beer AJ, Ziegler SI, Krause BJ, Schwaiger M et al. Assessment of tumor volumes in skull base glomus tumors using Gluc-Lys [(18)F]-TOCA positron emission tomography. Int J Radiat Oncol Biol Phys 2009;73:1135-40.
77. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003;98:1056-64. (Pubitemid 36460897)
78. Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery -in malignant glioma. Annals of Nucl Med 2004;18:291-6. (Pubitemid 39100096)
79. Yamane T, Sakamoto S, Senda M. Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging 2010;37:685-90.
80. Braun V, Dempf S, Weller R, Reske SN, Schachenmayr W, Richter HP. Cranial neuronavigation with direct integration of (11) C methionine positron emission tomography (PET) data -results of a pilot study in 32 surgical cases. Acta Neurochirurgica 2002;144:777-82; discussion 82.
81. Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004;45:1293-8. (Pubitemid 47618525)